A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.
Inclusion Criteria:
Exclusion Criteria:
Sandeigo, California 92103, United States
Str. Octavian Goga Nr. 17, Arad 310022, Romania
Bdul Nicolae Grigorescu Nr. 41, Bucharest 030440, Romania
Sos. Berceni Nr. 10-12, Bucharest 041914, Romania
Str. Negru Voda Nr. 53, Pitesti 110069, Romania
Kherson,vil., Stepanovka 73488, Ukraine
Kyviv, Ukraine